Follow-up With CT-FFR in CHD Patients After DCB (NCT04664439) | Clinical Trial Compass
UnknownNot Applicable
Follow-up With CT-FFR in CHD Patients After DCB
China92 participantsStarted 2021-06-01
Plain-language summary
In recent years, based on CCTA data, CT-derived fractional flow reserve (CT-FFR) developed by artificial intelligence and other technologies can provide both anatomical and functional information of coronary artery disease. Compared with CCTA alone, CT-FFR has a better ability to diagnose coronary ischemic lesions and can effectively reduce the need for unnecessary ICA, to predict revascularization more accurately.
Who can participate
Age range18 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Be able to understand the purpose of the test and sign the informed consent form.
✓. 6-12 months after DCB for coronary heart disease, there is no contraindication of coronary artery CTA examination.
✓. Non-target lesions of unplanned revascularization within 6 months.
✓. According to the clinical manifestations and auxiliary examinations (such as EET, SPECT, CCTA), the attending doctor will make a comprehensive judgment on the patients who plan to undergo ICA.
✕. Persistent or active symptoms of clinical instability, including acute chest pain (sudden onset), cardiogenic shock, unstable blood pressure (systolic blood pressure less than 90 mmHg), severe congestive heart failure (NYHA heart function III or IV) or acute pulmonary edema.
✕. Acute myocardial infarction occurred within 7 days before selection.
✕. Patients with other severe diseases are not suitable to participate in clinical trials, such as history of complex congenital heart disease, sick sinus syndrome, long QT syndrome, severe arrhythmia or tachycardia, severe asthma, severe or extremely severe chronic obstructive pulmonary disease, chronic renal dysfunction (serum creatinine level \> 2.0mg / dl or creatinine clearance \< 30ml/ Kg ·1.73m2).
✕. Allergic to iodinated contrast medium.
What they're measuring
1
Proportion of non-obstructive coronary heart disease in ICA examination
Timeframe: Clinical follow-up at 6 months after ICA or CT-FFR